OpGen, Inc, has launched the Acuitas™ MDRO Gene Test, a comprehensive molecular screening tool that can directly detect as many as seven genes from one patient sample, and will help hospitals and public health officials combat some of the most critical multi-drug resistant organisms (MDROs) threatening patients in healthcare facilities.

Unlike current microbe detection methods based on growing cells in laboratory culture, the Acuitas test uses highly sensitive molecular technology to detect antibiotic resistant genes within 24 hours.  It can distinguish specific genes that may aid in therapeutic guidance. Molecular technologies have been shown to have sensitivity greater than 95 percent, better assuring that at-risk patients are not missed.

“The Acuitas MDRO Gene Test is a significant development in our efforts to maintain the safety of patients against multi-drug resistant organisms.  The strength of this technology is based on the more accurate genomic approach to the detection of highly transmissible genes as opposed to traditional bacterial culture.  In addition, it can help to identify those patients who harbor MDROs, which may increase their risk for infection,” said James W. Snyder, Ph.D., Professor of Pathology and Laboratory Medicine at the University of Louisville School of Medicine.

The Acuitas MDRO Gene Test is currently performed at the CLIA-certified OpGen Clinical Services Laboratory in Gaithersburg, Maryland.